BNZ 1

Drug Profile

BNZ 1

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioniz
  • Developer Bioniz; National Institutes of Health (USA)
  • Class Anti-inflammatories; Antineoplastics; Peptides
  • Mechanism of Action Immunomodulators; Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cutaneous T cell lymphoma; T-cell leukaemia
  • Phase I Alopecia areata
  • Preclinical Adult T-cell leukaemia-lymphoma; Tropical spastic paraparesis

Most Recent Events

  • 04 Jun 2018 Bioniz Therapeutics plans a phase II trial for Alopecia Areata in October 2018 (NCT03532958)
  • 01 May 2018 Adverse events and pharmacodynamics data from a phase I trial in healthy volunteers released by Bioniz Therapeutics
  • 01 May 2018 Bioniz Therapeutics plans clinical trials for Alopecia areata
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top